Mid-cap Pharma Company might get a booster dose.
Updated
Mid-cap Pharma Company might get a booster dose?
The 31,177.59 Cr. worth mid-cap Pharma company, Laurus Labs Ltd. gave a massive 96% CAGR (3yrs.) in the past. The share price of the company made a high of Rs. 723.55 after which it saw a downturn is now giving signals of its trend reversal to Bullish. The share price of the company made an 'inverted Head and Shoulders' pattern which is a bullish trend reversal pattern. Also, the share price might also see a 50 & 100 EMA crossover in the next 1-3 trading session which again makes it a positive for traders & investors. In clear words, the target for the share is 665 - 685, with a mid-term view of 2- 12 weeks. The stock might retest the level of 550 - 560 (precisely Rs. 555) which would also make it the ultimate support.
Also, please consult your financial advisor before entering into any trade. This piece of knowledge is shared only for educational purposes. Thank You & keep learning!
The 31,177.59 Cr. worth mid-cap Pharma company, Laurus Labs Ltd. gave a massive 96% CAGR (3yrs.) in the past. The share price of the company made a high of Rs. 723.55 after which it saw a downturn is now giving signals of its trend reversal to Bullish. The share price of the company made an 'inverted Head and Shoulders' pattern which is a bullish trend reversal pattern. Also, the share price might also see a 50 & 100 EMA crossover in the next 1-3 trading session which again makes it a positive for traders & investors. In clear words, the target for the share is 665 - 685, with a mid-term view of 2- 12 weeks. The stock might retest the level of 550 - 560 (precisely Rs. 555) which would also make it the ultimate support.
Also, please consult your financial advisor before entering into any trade. This piece of knowledge is shared only for educational purposes. Thank You & keep learning!
Note
The Buying Zone/ Support range is updated to the area near the Green coloured line shown in the chart.
Disclaimer
The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.